Abstract: The use of thrombolytic therapy has been widely accepted for the treatment of acute myocardial infarction. Despite improving mortality, thrombolytic therapy may be contralndicated in many patients presenting with myocardial infarction and is associated with a small, yet significant risk of hemorrhagic sequelae. This article outlines thl rationale behind reperfusion therapy, the use of pharmacological thrombolysis and the role of adjunctive angioplasty. The potential advantages of a therapeutic strategy of primary angioplasty, instead of thrombolysis, are discussed. These include anatomical definition, risk stratification, reduced recurrent ischemia. enhanced coronary perfusion and improved coronary patency. The randomized trials in which primary angioplasty and thrombolytic therapy were compared are reviewed. We conclude that angioptasty results in a reduction of short-term mortality and nonfatal reinfarction and therefore advocate the routine use of coronary angioplasty as a primary reperfusion strategy for acute myocardial infarction. The potential limitations of primary angioplasty in the cornmunity hospital setting are discussed. Finally, we examine the roles of adjunctive mechanical (e.g. stents) and pharmacological (e.g. Abciximab) means of further enhancing outcomes atter primary angioptasty.
Introduction
Despite the decline in cardiovascular mortality over the last three decades, atherosclerosis still accounts for approximately 700 000 coronary artery disease-related deaths per year and over I 000 000 acute myocardial infarctions (AMI)' in the USA alone. The reduced individual mortality of myocardial Infarction' may be explained by earlier detection, more widespread use of coronary care units, increased knowledge of appropriate drug therapy and aggressive reperfusion therapy using both thrombolytic agents and balloon angioplasty. The relative benefits of thrombolytic therapy and primary angiopJasty in the setting of acute myocardial infarction continues to be an active area of investigation.
We believe substantial data exist supporting the routine use of percutaneous transluminal coronary angioplasty (PTCA) as a primary reperfusion strategy for acute myocardial infarction. This paper reviews the rationale and salient data supporting pharmacological and mechanical thrombolysis, whilst making an argument for direct angioplasty as the preferred therapy.
Pharmacological thrombolysis
The impetus for thrombolytic therapy was based on the observed high prevalence of coronary artery thrombosis in the early stages of myocardial infarction 1 and the demon-Subsequent studies in humans looking at indirect measurements of infarct size have confirmed these results.v? With the advent of coronary angioplasty in the late 1970s, early attempts to open acutely occluded coronary arteries using guide wires and catheters were only partially successful." Subsequently. intracoronary streptokinase was administered with promising results in an uncontrolled series of patients.') By the mid-1980s. the more practical approach of intravenous thrombolytic therapy was proven to positively impact on mortality in comparison with more conservative forms of treatment. 10.11 More recently. the GUSTO 1 trial demonstrated a mortality advantage of an accelerated dosage regimen of tissue plasminogen activator (I-PA) over streptokinase. 12 The combination of t-PA and intravenous heparin resulted in a 6.3%, 30-day mortality compared with 7.3% with streptokinase. There was however a 1.55% incidence of stroke in the t-PA arm and 1.3% in the combined streptokinase arms. Whilst it is known that thrombolytic therapy does not work instantaneously, there are little data on the time it actually takes to achieve infarct artery patency. Angiographic patency rates at 60 min from administration of thrombolysis are available from some studies. Accelerated dosage regimens of t-PA have been the most efficacious with 6O-min patency rates of 65-76%.13-16 These rates improve marginally over time to yield 90-min patency rates of 81-91%. [13] [14] [15] [16] Probably more important than the choice of thrombolytic agent, is the speed in which it is delivered. Several trials have shown that patients treated earlier into the course of their infarction have improved in-hospital mortality compared to those treated later.":" This is particularly so with treatment within the first hour, with in-hospital mortality rates as low as 1.2%.7 The level of coronary perfusion (or TlMI grade; Table 1 ) also appears to be extremely important. Subset analysis of the GUSTO I trial revealed that patients with TlMI grade 3 flow at 90 min had improved left ventricular function and improved 30-day mortality compared with those patients with TIMI grade 0 or I flow. 17 To date, the best pharmacological regimens have failed to yield TlMI grade 3 flow rates in nearly half of the treated patients.F"!"
Angioplasty as an adjunct to pharmacological thrombolysis
The role of angioplasty after the administration of thrombolytic therapy has been assessed in various clinical scenarios. It has been examined in the setting of successful thrombolytic therapy where routine elective angioplasty has been performed immediately, early and relatively late after thrombolytic therapy. Angioplasty has also been evaluated Table 1 Definitions of perfusion in the TIMI triafl9 Grade 0 (no perfusion) There is no antegrade flow beyond the point of occlusion.
Grade 1 (penetration without perfusion) The contrast material passes beyond the area of obstruction but 'hangs up' and fails to opacify the entire coronary bed distal to the obstruction for the duration of the cineangiographic filming sequence.
Grade 2 lpartial perfusion)
The contrast material passes across the obstruction and opacifies the coronary bed distal to the obstruction. However, the rate of entry of contrast material into the vessel distal to the obstruction or its rate of clearance from the distal bed (or both) are perceptibly slower than its entry into or clearance from comparable areas not perfused by the previously occluded vessel, e.g., the opposite coronary artery or the coronary bed proximal to the obstruction. in the setting of failed thrombolytic therapy. These strategies are all confounded by the lack of precise markers of successful reperfusion following intravenous administration of thrombolytic agents. Although resolution of chest pain, reperfusion dysrhythmias and normalization of ST segment changes have been clearly associated with successful thrombolysis, their absence does not reliably predict failure of reperfusion.
Immediate and early PTCA following thrombolysis Three large randomized trials have evaluated the role of routine early (within hours) angioplasty after the administration of thrombolytic therapy, despite the presence of a patient infarct-related artery.2(}'-22 The conclusions of each of these trials were an increase in bleeding complications, more emergent bypass surgery and higher mortality rates in the early angioplasty group. Surprisingly, there was also no reduction in the early reocclusion rates in the angioplasty group.
Late PTCA following thrombolysis
Routine angioplasty performed at a later time (after 18 h) interval has also been evaluated in a number of trials. 22-25 These trials did not show any difference between an early invasive approach versus a conservative approach, with respect to deaths, reinfarctions or left ventricular ejection fraction.
To date, there has been no study demonstrating additive benefit from the routine application of PTCA following successful thrombolysis, in any time frame. Thus, a policy of close supervision in patients treated with thrombolytic therapy with intervention only if there is evidence of ischemia, is a safe and valid approach.
'Rescue' angioplasty Only one, relatively small, randomized trial has looked at the use of angioplasty for patients whose infarct-related artery is not successfully reperfused by thrombolytic therapy." This trial demonstrated a favorable trend (p =0.05) for the composite endpoint of mortality and severe heart failure in a selected group of patients who underwent angioplasty of their occluded infarct-related artery when compared to a control group. In the subset of patients who underwent predischarge coronary angiography, infarct artery patency was 92% for the angioplasty group and 42% for the conservatively managed group (p::5 0.(01). This may represent the only scenario where angioplasty, in patients who have received thrombolytic therapy, is potentially beneficial. The concept of 'rescue' angioplasty is predicted on the presence of reliable markers of reperfusion. However, as mentioned, the traditional markers are far from reliable and therefore it is difficult to identify the patient subsets who may benefit from this approach.
Rationale behind direct PTCA
Direct or primary PTCA implies the use of emergency balloon angioplasty instead of thrombolytic therapy in patients suffering acute myocardial infarction. Most of the large thrombolytic trials have excluded many patients because of absolute and relative contraindications to thrombolytic The most feared complication of thrombolytic therapy is cerebral hemorrhage. which is less common in patients treated with direct PTCA. ",·N A notable advantage of primary PTCA over thrombolysis is the concomitant treatment of the underlying coronary stenosis. while establishing coronary patency through mechanical thrombolysis. This secondary benefit may be expected to reduce the incidence of recurrent ischemia and infarction. A lower residual stenosis after direct ungioplasty in comparison to thrombolytic therapy has been demonstrated in a number of trials. JhAO Rcocclusion of the infarct artery is associated with reduced left ventricular systolic function and increased in-hospital mortality.17AI The 0-month follow-up results from the primary angioplasty registry reported a low incidence of nonfatal reintarction (oCk) 10 Diagnostic coronary angioplasty is an obligatory antecedent of all direct PTCA strategies for AMI. This definitive documentation of coronary anatomy not only identifies the 'culprit infarct artery' for intervention but also guides subsequent management decisions. Patients with left main or severe triple vessel disease. who may benefit from surgical revascularization, are ident ified . Conversely. patients with minimal coronary disease can be identified for safe early discharge. Patients with a patent or insignificant infarct-related artery may be selected for medical management. thus avoiding the risks of thrombolytic therapy. In the PAMI (Primary Angioplasty in Myocardial Infarction) study.."I lOth of the patients randomized to angioplasty did not undergo the procedure because the infarct-related vessel was shown to be patent with minimal residual stenosis. or the patient was felt to be at high risk for complications associated with PTCA and was referred for emergency bypass grafting.
Patients with other disease processes masquerading as an acute infarct can be identifed and spared treatment with potentially dangerous thrombolytic agents by demonstrating coronary patency. Examples of such disease processes are :
therapy. Absolute contraindicutions have included recent or current bleeding. recent surgery. trauma or cerebrovascular accident. Relative contraindicutions have included very recent external cardiac compression. uncontrolled hypertension. suspected mural thrombus. known hemostatic disorders. prior anticoagulation therapy. pregnancy. severe concomitant medical conditions and hemorrhagic diabetic retinopathy . Some trials have also restricted entry to those patients aged less than 75 years. In a review of major thrombolytic trials by Grines et al.:
7 it was noted that as few as lOCK of patients in the USA with acute infarction actually received thrombolytic therapy . with the primary reasons for exclusion being long duration of chest pain and age greater than 75 years. In the GISSI trial.!" which allowed enrollment up to 12 h from symptom onset and did not exclude elderly people. only 37% of patients with AMI were enrolled in the study. The authors also noted that the mortality rates among patients 1101 enrolled in thrombolytic trials were significantly higher than those that were.
Few would disagree about the use of primary angioplasty in patients with contraindications to thrombolytic therapy. provided it can be performed in a timely fashion by experienced operators. However. there is continued debate about the relative benefits of primary angioplasty over the usc of thrombolytic therapy. The potential benefits of direct PTCA include:
• confirmation of diagnosis • complete anatomical definition • risk stratification • improved TIMI grade 3 flow rates • reduction in recurrent ischemia • reduction in hemorrhagic risks of thrombolytics • potentially lower cost.
One of the greatest advantages of PTCA over thrombolytic therapy is the higher primary success rate with respect to the establishment of patency of the infarct-related artery. In addition. determination of patency may be difticult to discern noninvasively when thrombolytics are used. whereas a strategy of primary angioplasty affords a direct and early assessment of patency.
The GUSTO angiographic investigators 17 demonstrated that among patients with partial flow through the infarctrelated artery (TIM} grade <2) at 90 min. ventricular function was worse and mortality higher than among patients with normal flow (Figure 2 ). The mortality rate in patients with TIMI grade 3 flow was 4.3 %, compared with 9'7c (p =0.0(9) in those with TIM} grade 0 or I flow. Mortality in patients with TIMI grade 2 flow was similar to that of patients with TIMI grade 0 or I flow (7.4%). Primary angioplasty has been reported to result in TIMI grade 3 flow rates of between 92£)'c and 97%.:x -JOThis compares to the TIMI grade 3 flow rates of 54-6OC k in the best available thrombolytic regimens in the GUSTO 1 17 and TEAM 2 trials. IX Survivors of myocardial infarction with a patent infarct artery have an improved short-and long-term outcome. when compared to those with an occluded artery. despite similar systolic left ventricular function.">" Sustained patency of the infarct-related artery has also been associated with improved left ventricular function. 17 ._" Late patency rates of between 87(k and 91 Ck'617 have been reported in primary angioplasty trials. This is a higher percentage than that reported with thrombolytic therapy. ",.lX and hospital readmission for ischemia (10%), which they reported as comparable or better than the best results with thrombolytic therapy." Subsequent prospective randomized trials comparing primary coronary angioplasty with thrombolytic therapy have confirmed a reduction in recurrent ischemia in those patients treated with primary angioplasty. 36, 42, 43 A strategy of direct PTCA may also be cost saving. Short-term follow-up studies have shown that hospital stays are shorter and costs comparable or lower with direct PTCA in comparison to thrombolytic therapy.42,43 Analysis over a 12-month period also found similar costs for each of these two strategies. Direct costs did not significantly differ between the two groups, although there was a trend to lower costs in the direct PTCA group when analyzed by intention to treat. Indirect measures of cost showed a trend in the direct angioplasty group towards a shorter hospital stay and fewer late in-hospital procedures, whilst measures of quality of life were similar for the two treatments.r':" These data suggest that the initial higher cost of PTCA is offset by earlier discharge, fewer recurrent ischemic events and less readmissions.
History of primary angioplasty for MI
In the early 19805, the use of angioplasty for the treatment of myocardial infarction was described in nonrandomized cohorts of patients with or without preceding thrombolytic therapy.46,47 High rates of infarct-related artery patency, attained with relative safety, were reported for the group overall; however, no conclusions could be made with respect to relative benefits on mortality, of strategies of thrombolysis versus PTCA with thrombolysis or PTCA alone. Subsequently, whilst the routine use of coronary angioplasty after thrombolytic therapy was demonstrated to be of no clear advantage over thrombolytics alone, the role of angioplasty as the primary treatment in acute myocardial infarction remained undetermined.
In an early, consecutive series of 500 patients who underwent primary angioplasty for AMI, O'Keefe et al reported a success rate of 94%, an urgent coronary artery bypass graft (CABG) surgery rate of 2% and an in-hospital mortality rate of 7.2%.31 Of hospital survivors, 95% were alive at 1 year and 84% at 5 years. Though unrandomized, this clinical trial demonstrated that a strategy of direct PTCA could be performed safely and with good results both initially and at long-term follow-up.
A small, prospective randomized trial of direct PTCA versus intracoronary thrombolysis within 12 h of the onset of symptoms of AMI, revealed a similar rate of early coronary reperfusion and incidence of postinfarct angina with either treatment." There was, however, a significant reduction in the residual stenosis after angioplasty compared with intracoronary streptokinase (43% versus 83%; p < 0.001). Initial randomized trials in which patients were assigned to receive either immediate PTCA or intravenous thrombolytic therapy, lacked the statistical power to detect differences in clinical outcome between the two treatment groupS.4R. 49 A 395-patient multicenter trial, the PAMl study. comparing t-PA therapy with primary angioplasty in acute myocardial infarction, was reported in 1993. 39 The angioplasty sueYascular Medicine 1997; 2: 327-334 cess rate was 97% and no patient required emergency bypass graft surgery for a failed procedure. PTCA resulted in reduced in-hospital rates of mortality (2.6% versus 6.5%, p=O.06) and reinfarction or death (5.1% versus 12.0%, p =0.02), whilst intracranial bleeding occurred more frequently in the t-PA group (2.0% versus 0%, p =0.05).
There was no difference in the rest or exercise ejection fractions between the two groups. At 6 months, reinfarction or death occurred in 16.8% of t-Pa-treated patients compared with 8.5% of the PTCA-lreated patients (p =0.02). A similar study was undertaken in Europe to compare a strategy of immediate PTCA with intravenous streptokinase therapy in the treatment of patients with acute myocardial infarction." Immediate angioplasty compared with intravenous streptokinase therapy in acute myocardial infarction was associated with a higher infarct-related artery patency at follow-up (91% versus 68%, p =0.00 I), a less severe residual stenotic lesion (36% versus 76%. p < 0.001), better left ventricular ejection fraction at discharge (51% versus 45%, p =0.004), less recurrent myocardial ischemia (9% versus 38%. p < 0.001) and less reinfarction (0% versus 13%, p =0.003). Three patients in the PTCA group had anatomy unfavorable for PTCA and so had emergency CABG surgery. In one other patient the infarct-related vessel could not be reopened and this patient underwent immediate coronary artery bypass grafting.
Despite apparent mortality benefits, immediate angioplasty may not result in greater myocardial salvage when compared to tissue plasminogen activator. A study assessing the change in the size of perfusion defect using technetium99m sestamibi myocardial perfusion scans, showed no significant difference between these two groups." Thus. in these landmark studies, immediate angioplasty was more effective than thrombolytic therapy in restoring patency, preventing reocclusion of the infarct-related artery and reducing the incidence of recurrent ischemia, reinfarction and death. It should be noted that, whilst patients who underwent immediate angioplasty had a shorter hospital stay, lower follow-up costs and fewer readmissions than those who received thrombolytic therapy, these trials were performed at facilities equipped and experienced in interventional coronary procedures. Coronary bypass surgical back-up was an important component of the PTCA treatment strategy. since a small, but significant, percentage of subjects assigned to undergo PTCA may require immediate bypass grafting of lesions unfavorable for PTCA or after complications of the PTCA itself.
A long-term (mean of 18 months) follow-up study of outcomes after randomization to intravenous streptokinase treatment or primary angioplasty for AMI, revealed a larger relative risk of death from cardiac causes and nonfatal reinfarction of 6.1 (Cl =2.9-12.7), and a higher 'weighted unsatisfactory outcome score' (including combined endpoints of death, stroke, heart failure, shock. EF < 30%.
reinfarction, reocclusion and bleeding complications) for the streptokinase group compared with PTCA,50 Revascularization was also performed more frequently in the streptokinase group (relative risk of 2.1; CI =1.5-3.2). These results support a more favorable long-term outcome overall. using PTCA as primary therapy in the setting of AMI.
A meta-analysis of data pooled from seven randomized trials of AMI, in which direct PTCA and thrombolytic therapy were compared, demonstrated a reduction in 6-week mortality (odds radio. 0.56: 95% CI = 0.33-0.94). and in short-term mortality and nonfatal reinfarction combined (odds ratio, 0.53; 95% CI = 0.35-0.80). 51 Goldman in his cost effectiveness analysis, pooled results of three randomized trials and suggested that primary angioplasty can reduce mortality by as much as 63% without any increase in cost. This potential benefit is substantially greater than the 10%to 15%relative mortality rate reduction for each hour earlier that thrombolytic therapy is administered or the 12% relative benefit suggested for accelerated t-PA compared with that for streptokinase."
Adjunctive use of intra-aortic balloon pump after direct PTCA A number of adjunctive treatments have been combined with a strategy of direct PTCA for AMI. Observational data on the adjunctive use of an intra-aortic balloon pump (IABP) in AMI suggested that. after establishment of coronary artery reperfusion with thrombolytics, aortic counterpulsation could reduce the rate of reinfarction or reocelusion of the infarct-related artery. Bleeding complication rates were significantly higher with the IABP than without it and a vascular complication rate of 12% was observed.51
The PAMI-2 study.":" investigated the role of the IABP in combination with PTCA for AMI. Coronary angiography was used to stratify patients with acute myocardial infarction into high-and low-risk groups. Mortality of the highrisk patients was 5.5% compared with O.3 ck in the lowrisk group (p < 0.000 I). Additionally, a low-risk. very low mortality population was able to be identified and discharged from hospital on day 3. Patients stratified to the high-risk group were randomized to IABP or no IABP during and/or after angioplasty. Using IABP after angioplasty in the high-risk group could be done safely. with no increase in vascular complications, sepsis or the need for transfusion. However, whilst IABP use reduced in-hospital ischemic events. it did not reduce the endpoint of cumulative death. recurrent MI. reocclusion, stroke or congestive heart failure. s657 We believe that the routine use of IABP following direct angioplasty should be limited to those patients who have hemodynamic indications for aortic counterpulsation.
Adjunctive pharmacology follewlng direct PTCA The GUSTO lIb study compared the clinical efficacy of a direct thrombin inhibitor. recombinant hirudin. with that of heparin (an indirect antithrombin agent) in patients with unstable angina or AMI treated with thrombolytic therapy. A small advantage with hirudin over heparin. related principally to a reduction in the risk of nonfatal myocardial infarction was found. but with the beneficial effect dissipating over time. This result called into question the existence of a pivotal role for thrombin in acute coronary thrombosis." Platelet glycoprotein lIb/lIla receptors modulate the final common pathway for platelet aggregation and consequently have been postulated to be of importance in occlusive coronary syndromes. The use of a platelet glycoprotein lIb/lIla receptor inhibitor, c7E3. has been shown to reduce 30-day ischemic endpoints after high-risk angioplasty by 35% and 6-month ischemic events by 23%. hut with an increase in the number of in-hospital bleeding episodes. 61 The increased risk of bleeding in patients receiving c7E3 (24% versus 13%. p = 0.28), underlines the major drawback of its use in coronary angioplasty, although it should be noted that most of the major bleeding events reported in this trial occurred in the rescue angioplasty group, in whom thrombolytic therapy had already failed. Additionally. new data from the EPILOG trial suggests that using c7E3 with 'low-dose' weight-adjusted heparin. resulted in the same reduction in composite ischemic endpoints with major bleeding rates that were less than the placebo and 'standard dose' heparin arms/" These data provided evidence of potential benefit of glycoprotein lib/lIla receptor blockade during PTCA for AMI. Further investigation of the use of c7E3 in the setting of primary PTCA alone is currently being undertaken.
Stenting following direct PTCA Whilst primary PTCA results in a very high rate of patency of the infarct-related artery. in those cases where patency is not maintained. mortality may be significantly increased. Coronary stenting has been successfully used in the management of acute or threatened occlusion complicating elective coronary angioplasty.v'<" In addition. elective stenting has been shown to improve outcomes compared with elective PTCA in randomized trails. f16 • 67 However. a strategy of stent implantation at the time of primary PTCA for AMI. had been avoided because of the perceived increased risk of stent thrombosis in this setting. Early case reports described the successful use of stents to treat complications of primary PTCA for AMI.
6H
M Coronary stents can be implanted in the setting of AMI. after failed or suboptimal PTCA result with a high degree of procedural success and safety and a low incidence of early recurrent ischernia.?". . . 7 .\ The PAMI stent pilot study demonstrated that primary stenting in AMI is safe and feasible in the majority of patients. and results in excellent short-term outcomes." Of the 151 stented patients. in-hospital events rates appeared superior to experience with primary PTCA: death 0.7%, reinfarction 1.4%. recurrent ischemia 2.8 ck and predischarge PTCA 1.4%. Preliminary results of the first 93 patients from the ESCOBAR trial. a randomized trial comparing a primary stent strategy with primary PTCA in AMI. demonstrated safety of the stent strategy and at early follow-up. a significantly lower combined endpoint of death. reintervention or recurrent AMI (p = 0.(3),76 With such low early event rates, it seems unlikely that adjunctive therapy, such as the use of c7E3, will have a major impact on a strategy of primary stenting in AMI. though an effect on more longterm factors. such as restenosis, can not be discounted.
Community practice and primary PTCA It may not be reasonable to extrapolate the results of these interventional trials to smaller or community-based hospital practice. The data supporting angioplasty as a preferred approach for AMI have emerged, for the 1110st part. from a few large volume centers where highly skilled operators have performed the procedures. The number of patients in the direct angioplasty trials is small in comparison to the thousands of patients who have been studied with intravenous thrombolysis. A small retrospective analysis of primary angioplasty performed in a community hospital setting was presented recently in abstract form. These authors reported unsuccessful primary angioplasty in 20 out of 37 patients, of which nine required emergent coronary artery bypass surgery." The MITI project registry investigators observed no benefit on mortality between strategies of primary angioplasty and thrombolytic therapy in a large, unrandomized cohort of patients with AMI (5.5% versus 5.6%; p =0.93).78 Additionally, the mean total cumulative inpatient costs were 13% lower at 3 years in patients treated with thrombolytic therapy. Whilst these findings may reflect the effectiveness of these therapies in the uncontrolled setting of community hospital practice, limitations of this report include problems inherent in the use of medical record review to ascertain event rates and the fact that angioplasty success rates were much lower than that reported by the PAMI investigators (89% versus 97%). This may in part be accounted for by a combination of performance of interventions in smaller volume centers along with improvements in current PTCA technique and equipment that have occurred since this registry began in 1988.
Conclusion
A strategy of primary or direct coronary angioplasty in the setting of acute myocardial infarction may be performed safely with good clinical outcomes and at a similar cost to thrombolytic therapy. Primary angioplasty may have an advantage over thrombolytic therapy by enabling a higher rate of success at restoring arterial patency, a reduction in the severity of residual stenosis in the infarct-related artery and a lower rate of recurrent ischemia. This can be achieved with low in-hospital mortality and stroke rates. Additionally, this strategy allows for earlier identification of patients requiring coronary bypass graft surgery for three vessel or left main disease, and for stratification of patients into a low mortality risk group, who can be safely discharged home early.
Implantation of coronary stents in patients with AMI appears to further improve initial success rates of angioplasty and the short-term rates of reinfarction, death and reintervention. Long-term outcomes after primary stenting and the role of palatelet glycoprotein IIblIIIa receptor inhibitors, in the setting of acute myocardial infarction, are yet to be elucidated.
